# Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

> **NCT04521153** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 294 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Immunotherapy
- Molecular Targeted Therapy

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate
- **PROCEDURE:** Radical surgery

## Key facts

- **NCT ID:** NCT04521153
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-25
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-03-01
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521153, "Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04521153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*